Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

Paclitaxel 7Specimen Handling 6Radiotherapy 4Magnetic Resonance Spectroscopy 4Biopsy 4pembrolizumab 3Taxes 3Nivolumab 3Carboplatin 3trastuzumab deruxtecan 2olaparib 2ceralasertib 2aflibercept 2X-Rays 2Psychiatric Rehabilitation 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Ifosfamide 2Gene Expression Profiling 2Fulvestrant 2Filgrastim 2Fentanyl 2Doxorubicin 2Bevacizumab 2trifluridine tipiracil drug combination 1toripalimab 1tinostamustine 1spartalizumab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × pelcitoclax × Sarcoma × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡